A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes

Exclusion Criteria

• •1. Known or suspected allergy to the investigational drug product or its components or excipients;
• •2. Systemic glucocorticoid use within 3 months prior to screening
• •3. Use of weight loss drugs within 3 months prior to screening
• •4. Insulin therapy other than basal insulin was used within 3 months prior to screening
• •5. Cardiovascular disease, defined as congestive heart failure (NYHA III-IV), unstable angina pectoris, stroke (except lacunar infarction without symptoms), myocardial infarction, coronary revascularization within 6 months prior to screening; And/or coronary, carotid, or peripheral arterial revascularization is planned at screening
• •6. (with or without treatment) uncontrolled severe hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg)
• •7. Proliferative retinopathy or macular degeneration requiring acute treatment, painful diabetic neuropathy, diabetic foot ulcers, intermittent claudication at screening;
• •8. Patients diagnosed with mental disorders; Mentally incapacitated or speech impediment, unable to fully understand the trial protocol or unwilling to collaborate;
• •9. Known or suspected abuse of alcohol or narcotics;
• •10. Previous history of pancreatitis (acute or chronic)
• •11. During pregnancy or lactation;fertile women (WOCBP) or men who have fertility plan or unwilling to use appropriate contraceptive methods from the signing of the informed consent to 3 months after last use of the investigational drug product;
• •12. Any condition, determined by the investigator, interfere with the efficacy or safety results of the trial.